Literature DB >> 18666820

Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons.

Jean-Pierre Pouget1, Lore Santoro, Laure Raymond, Nicolas Chouin, Manuel Bardiès, Caroline Bascoul-Mollevi, Helena Huguet, David Azria, Pierre-Olivier Kotzki, Monique Pèlegrin, Eric Vivès, André Pèlegrin.   

Abstract

To improve radioimmunotherapy with Auger electron emitters, we assessed whether the biological efficiency of (125)I varied according to its localization. A-431 and SK-OV-3 carcinoma cells were incubated with increasing activities (0-4 MBq/ml) of (125)I-labeled vectors targeting the cell membrane, the cytoplasm or the nucleus. We then measured cell survival by clonogenic assay and the mean radiation dose to the nucleus by assessing the cellular medical internal radiation dose (MIRD). The relationship between survival and the radiation dose delivered was investigated with a linear mixed regression model. For each cell line, we obtained dose-response curves for the three targets and the reference values (i.e., the dose leading to 75, 50 or 37% survival). When cell survival was expressed as a function of the total cumulative decays, nuclear (125)I disintegrations were more harmful than disintegrations in the cytoplasm or at the cell membrane. However, when survival was expressed as a function of the mean radiation dose to the nucleus, toxicity was significantly higher when (125)I was targeted to the cell membrane than to the cytoplasm. These findings indicate that the membrane is a more sensitive target than the cytoplasm for the dense ionization produced by Auger electrons. Moreover, cell membrane targeting is as cytotoxic as nuclear targeting in SK-OV-3 cells. We suggest that targeting the membrane rather than the cytoplasm may contribute to the development of more efficient radioimmunotherapies based on Auger electron radiation, also because most of the available vectors are directed against cell surface antigens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18666820     DOI: 10.1667/RR1359.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  28 in total

1.  Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitter.

Authors:  Maryline Gardette; Janine Papon; Mathilde Bonnet; Nicolas Desbois; Pierre Labarre; Ting-Dee Wu; Elisabeth Miot-Noirault; Jean-Claude Madelmont; Jean-Luc Guerquin-Kern; Jean-Michel Chezal; Nicole Moins
Journal:  Invest New Drugs       Date:  2010-06-22       Impact factor: 3.850

2.  A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers.

Authors:  Raghu Raghavan; Roger W Howell; Michael R Zalutsky
Journal:  Biomed Phys Eng Express       Date:  2017-05-05

3.  Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.

Authors:  Jürgen Grünberg; Dennis Lindenblatt; Holger Dorrer; Susan Cohrs; Konstantin Zhernosekov; Ulli Köster; Andreas Türler; Eliane Fischer; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-24       Impact factor: 9.236

4.  Monte Carlo single-cell dosimetry using Geant4-DNA: the effects of cell nucleus displacement and rotation on cellular S values.

Authors:  Ramak Salim; Payvand Taherparvar
Journal:  Radiat Environ Biophys       Date:  2019-03-29       Impact factor: 1.925

5.  64Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer.

Authors:  Yukie Yoshii; Hiroki Matsumoto; Mitsuyoshi Yoshimoto; Yoko Oe; Ming-Rong Zhang; Kotaro Nagatsu; Aya Sugyo; Atsushi B Tsuji; Tatsuya Higashi
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

6.  Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.

Authors:  Il Minn; Ying Chen; Ana P Kiess; Robert Hobbs; George Sgouros; Ronnie C Mease; Mrudula Pullambhatla; Colette J Shen; Catherine A Foss; Martin G Pomper
Journal:  J Nucl Med       Date:  2015-07-16       Impact factor: 10.057

7.  Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic.

Authors:  Eftychia Koumarianou; Tatiana A Slastnikova; Marek Pruszynski; Andrey A Rosenkranz; Ganesan Vaidyanathan; Alexander S Sobolev; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-04-02       Impact factor: 2.408

8.  In vitro proof of concept studies of radiotoxicity from Auger electron-emitter thallium-201.

Authors:  Vincenzo Abbate; Samantha Y A Terry; Katarzyna M Osytek; Philip J Blower; Ines M Costa; Gareth E Smith
Journal:  EJNMMI Res       Date:  2021-07-05       Impact factor: 3.138

9.  Physical Considerations for Understanding Responses of Biological Systems to Low Doses of Ionizing Radiation: Nucleosome Clutches Constitute a Heterogeneous Distribution of Target Volumes.

Authors:  Roger W Howell
Journal:  Health Phys       Date:  2016-03       Impact factor: 1.316

10.  Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis.

Authors:  Lore Santoro; Samir Boutaleb; Véronique Garambois; Caroline Bascoul-Mollevi; Vincent Boudousq; Pierre-Olivier Kotzki; Monique Pèlegrin; Isabelle Navarro-Teulon; André Pèlegrin; Jean-Pierre Pouget
Journal:  J Nucl Med       Date:  2009-11-12       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.